CLEAR CELL RENAL CELL CARCINOMA

This early-phase trial tests a new treatment for advanced kidney cancer that has spread. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The study will enroll 18 adults and focus on safety and finding the right dose, w…

This study tests whether giving a combination of two drugs (a PD-L1 inhibitor called TQB2450 and anlotinib) before surgery can shrink complex kidney tumors enough to allow surgeons to remove only the tumor and save the rest of the kidney. About 33 adults with advanced clear cell …

This study tests whether giving a combination of three drugs (pembrolizumab, belzutifan, and lenvatinib) before surgery can shrink kidney tumors in people with localized clear cell renal cell carcinoma. About 150 participants will receive the drugs for 12 weeks before surgery, th…

This pilot phase II trial tests whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for patients with high-risk clear cell kidney cancer that hasn't spread. Sixteen participants will receive the drugs and then undergo surgery …

This early-phase trial is testing a new treatment called LNK001 for people with advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to standard treatments. LNK001 is a type of immunotherapy where a patient's own immune cells are…

This phase 2 trial tests a new drug called zanzalintinib, taken as a pill, combined with a bone-strengthening agent for people with advanced kidney cancer that has spread to the bones. The study enrolls 20 participants whose cancer has worsened after 1–3 prior treatments, includi…

This study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib or axitinib) in 36 adults with advanced clear cell kidney cancer that has worsened after initial treatment. The main goal is to see if the combination can …

This phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…

This study tests a combination of two drugs—envafolimab (an immunotherapy injection) and axitinib (a targeted therapy pill)—as a first treatment for people with advanced kidney cancer that has spread or cannot be removed. About 30 participants will receive the treatment for up to…

This study looks for protein markers in urine and blood that could help identify different types of kidney cancer without needing a biopsy. Researchers will analyze stored urine samples from 300 people and collect blood before and after kidney removal surgery. The goal is to deve…

This early study will look at how two drugs, cabozantinib and nivolumab, change the bone immune environment in 16 people with kidney cancer that has spread to bone. The main goal is to check safety and see how the bone environment responds. It is a proof-of-concept study, meaning…